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Abstract: Sporadic Parkinson’s disease is a widespread human disease that has never been reported in non-human verte-
brates. The etiopathogenesis of the non-motor symptoms in the disease is not well understood and it is difficult to inter-
pret the roles of affected neurotransmitters in currently available animal models. Most of the non-motor symptoms do 
not correlate with the stage of motor deficits and precede the development of motor symptoms by many years, before the 
permanent loss of dopaminergic neurons in the basal ganglia. The aim of this review is to briefly summarize the advantag-
es and limitations of the well-recognized mammalian animal models with special regard to the non-motor complications 
of the prodromal and early stage Parkinson’s disease.
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It has been almost two centuries since James Parkinson published his monograph entitled 
“An essay on the Shaking Palsy” and still, there is no cure for the disease [1]. These days 
we are at least aware of the very complex nature of the sporadic Parkinson’s disease (PD). 
It affects all races equally, with slight male predomination. In Europe, the prevalence is 
1.6/100 inhabitants, with a  wide variability between different countries [2]. Its complete 
clinical manifestations consist of the more obvious motor symptoms such as resting trem-
or, hypokinesia, rigidity, postural instability [3] as well as less obvious, yet burdensome, 
non-motor symptoms including mainly olfactory, gastrointestinal, thermoregulatory and 
genitourinary dysfunction, sleep disturbances, anxiety, fatigue or even dental abnormali-
ties [4–7]. From the neuropathological point of view, it is defined by the continuous for-
mation of immunoreactive inclusion bodies, which develop only in susceptible neuronal 
types within the central and peripheral (including enteric part) nervous systems. The 
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inclusions occur in the form of spherical, granular Lewy bodies in cell somata as well as 
elongated, spindle-shaped or thread-like Lewy neurites in axons and dendrites [8–10]. 
These lesions, so called “Lewy pathology”, tend to play a key role in the pathogenesis of 
PD [8–13]. Only neurons with long, thin and weakly myelinated or unmyelinated axons 
become involved. Interneurons and projection cells with short axons or those with dense-
ly myelinated axons are not vulnerable [14–16]. It should also be mentioned that Lewy 
pathology is not limited to dopaminergic neurons of the substantia nigra but also occurs 
in glutamatergic [17, 18], noradrenergic, serotonergic [19], histaminergic, and cholinergic 
neurons. Thus, during the past decade, PD has come to be recognized as a multi-systemic 
disorder rather than a mono-systemic disease with selective dysfunction and loss of nigral 
neurons [8, 20–23].
For this review, relevant articles (full texts written in English language) were primarily 
identified by electronic search of the PubMed, Cambridge Journals Online and EBSCO da-
tabases (“non-motor symptoms” AND “Parkinson’s disease” AND “animal model”) as well as 
an examination of the reference lists of the identified studies and other distinguished reviews 
in the field. The majority of papers were published during the past decade.
Animal models of Parkinson’s disease
Sporadic Parkinson’s disease is a widespread human disease that has never been reported in 
non-human vertebrates [24]. This might partially explain the minimal translation of findings 
from the animal studies into the new effective treatments, with the exception of the deep 
brain stimulation which was tested in the MPTP-treated monkeys [25]. Still, animal models 
are a very important tool to improve our understanding of the pathogenesis and pathophys-
iology of the disease as well as for the testing of new therapeutic interventions [26]. The 
pathological process underlying PD consists of an early non-symptomatic period, followed 
by a prodromal phase, often characterized by olfactory dysfunction [27, 28], autonomic 
dysregulation [29], as well as sleep [30–33] and mood disturbances [34]. The non-motor 
features of PD [35] that can appear years, sometimes decades, before the onset of the motor 
symptoms, do not meaningfully respond to dopaminergic medication and are a challenge to 
the clinical management of PD [36–38]. The prodromal phase transitions into a phase that 
is accompanied by the classical somatomotor symptoms and subsequently, impaired cog-
nitive functioning. The duration of each phase varies among patients. Braak’s grading with 
six neuropathological stages incorporates all of them [8, 39] Thus, the “perfect” PD model 
should reproduce: the main pathological features such as cell loos in the substantia nigra 
and cytoplasmatic inclusions (in case of animals — Lewy-like pathology) possibly spreading 
from cell to cell manner, the progressive evolution of the neuronal damage, characteristic 
motor and non-motor symptoms, and finally be responsive to the therapeutics currently 
available in the market [26]. 
Up-to-date, such a model does not exist. Following a classical categorization strategy, 
existing animal models can be grouped into “fidelity models” and “discrimination models”. 
A fidelity model reproduces the maximum number of characteristics of the original, where-
as a  discrimination model reproduces only one particular characteristic of the original. 
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A high fidelity model might seem superior to a discrimination model, but the latter can 
help by teasing out the irrelevant factors from the important. Regarding PD modeling, the 
reserpine model sets an excellent example. This toxin works by inhibiting vesicular mono-
amine transporter 2, leading to a reversible depletion of monoamines. This model mimics 
the akinetic symptomatology of PD without being associated with the nigral dopaminergic 
cell degeneration. The model made it possible to demonstrate that dopamine was involved 
in the movement process so that L-DOPA was developed [40].
So far, epidemiological studies have suggested an association between environmental 
factors, including drinking well water, rural living, farming, exposure to agricultural chem-
icals, and PD. Elevated levels of organochlorines have been found in the brains of PD pa-
tients. Pesticides inhibiting the mitochondrial Complex I and increasing oxidative stress are 
more prone to induce PD upon exposure. Parkinson’s disease has also been linked to the 
exposure to different metals (manganese, lead, copper, iron, zinc, aluminium or amalgam) 
and industrial compounds. Higher incidence of PD has also been reported in manganese 
miners. Manganese, a component of various pesticides, reproduces Parkinsonian symptoms 
after long and chronic exposures (between 6 months and 16 years). Moreover, environmen-
tal toxins can induce the release of pro-inflammatory signals [41]. Hence, it is quite obvi-
ous that toxic models of PD remains the most popular. In animal models, the most widely 
used chemicals are MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) [42], 6-OHDA 
(6-hydroxydopamine) [43], rotenone [24, 44] and paraquat [45]. These models have been 
extensively reviewed in the literature [26, 40–50].
MPTP has been used to understand the effect of mitochondrial inhibition, to test dif-
ferent neuroprotective strategies or to observe the effect of dopamine absence in different 
brain functions and areas. MPTP produces an irreversible and severe parkinsonism in hu-
mans, characterized by all of the cardinal features of PD, including tremor, rigidity, slowness, 
postural instability and freezing, but it has two main drawbacks: firstly, induces only an 
acute or subacute neurodegeneration and secondly, neither Lewy bodies formation (except 
Lewy-like pathology in the locus coeruleus of older squirrel monkeys) nor the characteristic 
pathology progression has been observed so far [26, 40, 41]. There are also several meth-
odological limitations [49]. 
6-OHDA has to be injected directly in the central nervous system, as it is not able to cross 
the brain-blood barrier and when administered systemically, it destroys sympathetic neuron 
nerve terminals in the peripheral nervous system. Similarly, this model does not produce the 
characteristic Lewy-like pathology nor does it show the pathology progression. In fact, in 
case of 6-OHDA, it is more accurate to talk about at least two separate models: the medial 
forebrain bundle (more suitable for studying the consequences of dopaminergic neuronal 
death and to test therapeutic strategies to treat motor symptoms) and the striatal (more 
relevant to unmask the mechanisms of cell death involved in PD) [26, 40–43].  
Rotenone is a naturally occurring pesticide derived from the roots of plants within the 
Lonchocarpus and Derris genera and acts through mitochondrial Complex I inhibition [24]. 
The rotenone model largely gained its attention following the seminal paper by the Gre-
enamyre group, which demonstrated for the first time that rotenone administered sys-
temically to rats can reproduce the hallmarks of PD [51]. Fore mostly, chronic rotenone 
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treatment seems to generate proteinaceous inclusions in some of the surviving dopami-
nergic neurons that cannot be found in the standard 6-OHDA and MPTP models. These 
inclusions were first described in experiments with the osmotic pump administration 
and it remains to be determined if the daily injection regimen triggers the formation of 
the same kind of inclusions. Interestingly, the low dose prevents rotenone from reaching 
the brain but spreads the synucleinopathy from the enteric to the central nervous system 
[44–50]. Oral administration appears to cause little neurotoxicity. Thus, the chronic sys-
temic administration using osmotic pumps has been the most common delivery regimen, 
especially in the Lewis rat, which may be more sensitive to rotenone than other strains 
of rats [52]. 
Paraquat toxicity is mediated by the induction of redox cycling with a cellular diaphorase 
such as nitric oxide synthase, which gives rise to the subsequent production of reactive oxy-
gen species. As its chemical name indicates, paraquat is a pyridinium that shares structural 
similarities with another herbicide used in the past called cyperquat, which is an active ion 
of MPTP (MPP+). This fact suggested that both chemicals may share some mechanisms of 
neurotoxicity, though the exact details are still uncertain. Rotenone and paraquat models 
are not yet thoroughly understood (in the contrary to MPTP and 6-OHDA) and have to 
be fully validated, especially in terms of doses, routes of administration and experimental 
periods [26, 40, 41]. 
Less common model substances include lipopolysaccharide (acute and chronic admin-
istration), tetrahydroisoquinoline derivatives (such as salsolinol, for example) or another 
pesticide, maneb (especially in non-human primates) [26, 40, 48–50, 53, 54].
Regarding the molecular mechanisms of cell death, the toxin-based models have em-
phasized apoptosis, oxidative stress, mitochondrial dysfunction and microglial activation 
as key players in PD-related neurodegeneration. At the same time, they are not useful for 
screening of potential neuroprotectants, probably because of the acute nature of cell death 
in comparison with the natural progression of the disease [49].
Transgenic models are mostly associated with the familial cases of PD, however with 
some exceptions, for instance, the GBA1 gene encoding for lysosomal enzymes glucoce-
rebrosidase (GCase). Heterozygous mutations in the GBA1 gene are the most important 
risk factor for sporadic PD, leading to the 20 to 30-fold increased risk. Between 5 and 
10% of Parkinsonian patients carry such mutations. The loss of glucocerebrosidase ac-
tivity causes lysosomal dysfunction and α-synuclein aggregation [55]. Currently, in vivo 
models replicating such impairment are being developed, since mice with GCase defi-
ciency show mitochondrial impairment [56], enhanced vulnerability to PD-inducing mi-
tochondrial toxins (MPTP, MPP+) [57], gial activation and α-synuclein accumulation (in 
the cortex, hippocampus, substantia nigra and striatum) as well as dopaminergic synapse 
alterations including reduced striatal dopamine release and reduced post-synaptic density 
size [58]. 
Indeed, Parkinson’s disease seems to be heterogeneous in its etiology, and both, en-
vironmental and genetic factors should be taken into consideration. Perhaps the most 
promising models are those that could effectively combine genetic models with exposure to 
toxins.
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 Animal models of the non-motor symptoms in Parkinson’s disease
The non-motor symptoms in Parkinson’s disease appear throughout the course of the disease 
while some appear before motor symptoms are even fully recognized. In fact, the non-motor 
features remain under-recognized, under-researched, and under-treated [59, 60]. The early 
non-motor signs comprise impaired olfactory function, mood and personality disturbances, 
subtle neurocognitive dysfunctions and visuomotor control abnormalities. These signs and 
symptoms are neither specific nor sensitive for PD. However, in combination, they are highly 
suggestive for the disease [4, 6, 29]. The complete clinical manifestations, mainly due to the 
autonomic failure, include orthostatic hypotension, dry mouth, oropharyngeal dysphagia, 
upper gastrointestinal dysmotility, constipation, defecatory dysfunction, urinary urgency 
and urine incontinence, hyperhidrosis, and sexual dysfunction [29]. One should also bear in 
mind that besides those symptoms particularly attributable to pathologic changes in the ner-
vous system many of them represent adverse effects of the drug therapy, especially L-DOPA 
treatment. For instance, drug effects on the mesolimbic pathways can lead to impulse control 
disorders such as pathologic gambling and shopping, pending, binge eating and hypersex-
uality [61, 62]. Their effects on the autonomic system can cause the known non-motor side 
effects such as cardiovascular autonomic dysfunction (including orthostatic hypotension, 
syncope, impaired baroreflex, reduced heart rate variability), constipation, nausea and uro-
logical disturbances [63, 64]. Impulsive–compulsive behaviors constitute a serious clinical 
problem in PD because they interfere with a successful management of the motor symptoms. 
However, these type of the non-motor complications exceed the scope of this review [61].
The usefulness of toxic models for modeling the non-motor complications of the prodromal 
and early stage PD is limited by the fact that many of these symptoms are at least partially inde-
pendent of dopamine. The etiopathogenesis of the non-motor symptoms is not well understood 
and it is difficult to interpret the roles of each altered neurotransmitter systems in currently 
available models. Most of the non-motor symptoms do not correlate with the stage of the mo-
tor deficits and precede the development of the motor symptoms by many years [6, 7, 65, 30] 
before the severe and permanent loss of dopaminergic neurons in the basal ganglia [66, 67].
6-OHDA models have surely great value in studying the motor aspects of the PD and the 
efficacy of classical anti-parkinsonian drugs. However, the analysis of the non-motor symp-
toms seems to be rather limited. And it is also believed that the non-motor changes found 
in animals with complete 6-OHDA-induced lesions are closely linked to changes in dopa-
minergic function [68, 69]. According to literature, some of the neuropsychiatric non-motor 
symptoms of PD can be replicated in the 6-OHDA-induced rat model, suggesting the indirect 
involvement of various neurotransmitter systems. What is more, this model might also be 
used to mimic pain [70], circadian deficits [71] and gastrointestinal dysfunction [72, 73]. 
Zheng et al. have reported a reduce of dopaminergic neurons in the substantia nigra fol-
lowing the bilateral microinjection of 6-OHDA. 6-OHDA rats exhibited impaired gastric 
motility and delayed gastric emptying, accompanied by increased dopamine content and 
the over-expression of D2 receptors in the stomach. Subdiaphragmatic vagotomy prevented 
the increase in the gastric dopamine content and the dopamine D2 receptor expression and 
improved gastric dysmotility in 6-OHDA rats [74].
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A few studies have analyzed the MPTP-induced parkinsonism in non-human primates 
in search for deficient cognition. Similar phenomenon was found in rats, which displayed 
an impairment of memory acquisition and retention processes that was worsened with 
L-DOPA treatments [67]. It is likely that L-DOPA-induced increase in dopamine release 
in extrastriatal circuits can impair cognition in some PD patients while improving motor 
functioning [75]. At the same time, neither acute nor chronic exposure to MPTP in non- 
human primates was able to produce the sympathetic denervation of the heart [76] or in-
duce gastrointestinal dysfunction despite a significant decrease of neurons immunoreactive 
for tyrosine hydroxylase in the enteric nervous system [77]. 
MPTP-intoxicated monkeys exhibited deficits in maintenance of a response set and 
difficulties in shifting attention sets. Impaired ability to sustain spatial attention or to focus 
attention, deficits in motor readiness and planning and impaired time estimation was also 
observed in these animals. As in PD patients, these cognitive alterations are not reversed 
by L-DOPA. Instead, monkeys could also experience psychotic-like behaviors that may be 
related to the neuropsychiatric symptoms that PD patients often suffer from after chronic 
treatment with L-DOPA [40].
In an MPTP mouse model reported by Anderson et al., the toxin exposure caused 
a 57% decrease in neurons immunoreactive for tyrosine hydroxylase in the substantia nigra 
pars compacta, a 52% decrease in the striatum and a 40% reduction in the enteric nervous 
system 10 days after the injections. However, there were no changes in gastric emptying 
and most notably, the behavioral phenotype of gastrointestinal dysfunction was limited to 
a temporary increase in colonic motility (the opposite of what is observed in patients) [78]. 
Olfactory deficits are yet another complication difficult to replicate in the MPTP mouse 
model. It was shown a number of years ago that unlike Parkinsonian patients, individuals 
with MPTP-induced parkinsonism (usually due to parenteral self-administration) did not 
show any olfactory dysfunction [79]. Multiple studies also report lack of anxiety after MPTP 
exposure, suggestive of extranigral involvement in this frequent symptom in PD [80].
In general, the model of MPTP-induced parkinsonism has been extremely valuable in 
testing efficacy of dopaminergic therapies [81]. The toxin does not accurately replicate the 
global and progressive degeneration seen in the disease but its specificity can be used to 
help elucidate the role of dopamine in the development of some non-motor symptoms in 
PD. One should also remember that despite some similarities between the physiology of 
rodents and humans, it is clear that the significant differences do exist. For example, rats 
and mice are relatively resistant to MPTP, whereas humans are quite sensitive to this toxin. 
The sensitivity of humans to MPTP became apparent in 1983 when several drug addicts 
unfortunately injected themselves with MPTP thinking it was synthetic heroin. In rodents in 
order to produce some of the pathophysiological and behavioral symptoms seen in humans 
it is more effective to administer MPTP with probenecid (which blocks the rapid clearance 
of MPTP and its metabolites from the kidney) [49].
Rotenone administration in rats has been shown to lead to lesions of the nigrostriatal 
pathway and α-synuclein accumulation, yet the lack of specificity of the toxin and the vari-
ability of its effects in earlier experiments have limited its use for evaluating neuroprotective 
strategies. According to a growing body of literature, rotenone could mimic at least some 
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of the non-motor complications seen in PD patients [24, 26, 50, 67]. Rats that underwent 
bilateral infusion of rotenone into the substantia nigra displayed depressive behavior as well 
as changes to hippocampal levels of serotonin and noradrenaline metabolites [82]. Chronic 
rotenone administration also altered cognition in rats [83]. What is more, two groups have 
recently presented evidence that rotenone can induce gastrointestinal dysfunction as deter-
mined by α-synuclein aggregation in the enteric nervous system, loss of the myenteric neurons 
of the small intestine [84], a delay in gastric emptying and abnormal functioning of inhibitory 
neurons in the enteric nervous system [85]. Intragastric administration of rotenone in mice 
resulted in a progressive deposition of α-synuclein in both the enteric and the central neurons 
(the dorsal motor nucleus of vagus and the substantia nigra) [86]. One major advantage of the 
rodent rotenone model is its ability to induce the formation of a-synuclein-positive cytoplasmic 
inclusions in nigral neurons, replicating the neuropathological hallmark of Lewy bodies seen 
in PD. The major limitations of the rodent rotenone model include lack of reproducibility 
in the amount of animals that develop dopaminergic nigrostriatal lesions. However, despite 
the high variability of rotenone effects, the progressive and non-dopaminergic specificity of 
the toxin expands its experimental opportunities [24]. It also remains unknown whether 
the mechanisms of the non-motor complications observed in rotenone-treated animals are 
etiopathogenetically similar to those observed in PD patients [67]. 
Recently, Ngwa et al. have also demonstrated that V2O5 induces dopaminergic neuro-
toxicity via protein kinase C delta (PKCδ)-dependent oxidative signaling mechanisms in 
dopaminergic neuronal cells. Their results revealed a significant decrease in olfactory bulb 
weights, tyrosine hydroxylase levels, levels of dopamine and its metabolite, 3, 4-dihydroxy-
phenylacetic acid as well as increases in astroglia of the glomerular layer of the olfactory 
bulb in the treatment groups relative to vehicle controls. Neurochemical changes were ac-
companied by impaired olfaction and locomotion [87].
Unfortunately, few animal models recapitulate the non-motor symptoms in PD. The 
relationship between Lewy pathology, neurodegeneration and the corresponding clinical 
deficits awaits further elucidation [88].
Alpha-synuclein
Accumulating evidence suggests that sporadic Parkinson’s disease has a long prodromal pe-
riod during which various non-motor features start to develop. Early sites of Lewy pathology 
are the olfactory bulb and the enteric plexus [8, 11, 12]. Those eosinophilic intracytoplasmic 
neuronal inclusions are abnormal aggregates of proteins such as α-synuclein and ubiquitin, 
stored in the cytoplasm as non-degraded by-products of the degenerative process [14–16, 
20, 89]. The main component is α-synuclein which is abnormally phosphorylated, nitrated 
and oxidized, has an abnormal crystallographic structure and abnormal solubility, and is 
prone to the formation of aggregates and insoluble fibrils [90]. According to Braak et al., 
environmental or neurotropic pathogens might adhere to the mucous membrane of the up-
per gastrointestinal tract and/or nose and penetrate into local neurons, where they might 
trigger a formation of those pathological inclusions, which might be transported along un-
myelinated axons from the enteric nervous system to the dorsal motor nucleus of the vagus 
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nerve [8, 14, 15, 91]. Indeed, experimental models have made it possible to detect seeding 
mechanisms [92] and spreading of α-synuclein aggregates from the periphery via the vagus 
nerve to the central nervous system following intragastric, intraduodenal and peripheral 
vagal nerve inoculations [8, 93].
It is believed that the non-motor symptoms in PD are directly linked to widespread dis-
tribution of α-synuclein pathology not restricted to the dopaminergic nigrostriatal system. 
In addition to the non-nigral brainstem nuclei, α-synuclein pathology involves sympathetic 
and parasympathetic, enteric, cardiac and pelvic plexuses, and many other organs indicating 
a topographical and chronological spread [88, 94–96]. For example, Lewy bodies that contain 
α-synuclein are observed in central and peripheral regions associated with cardiovascular 
autonomic function such as the medulla, locus coeruleus, cardiac plexus and stellate ganglia. 
Furthermore, patients with a familial form of PD associated with duplication or triplication 
of the α-synuclein locus show impaired parasympathetic function in the Valsalva maneuver 
and reduced cardiac sympathetic innervation suggesting an important role for α-synuclein 
in the pathogenesis of sympathetic and parasympathetic dysfunction in PD [64]. 
Mutations of α-synuclein gene used to be mostly linked to monogenic forms of familial 
cases of Parkinson’s disease. The discovery of various mutations associated with those familial 
forms including α-synuclein, Parkin, DJ-1, ubiquitin C-terminal hydrolase L1 T (UCHL1), 
PTEN-induced putative kinase 1 (Pink1), and Leucine-rich repeat kinase (LRRK2) has led to 
the generation of genetic mouse models of parkinsonism [52, 97–99]. Genome-wide associa-
tion studies also suggested that sporadic PD is at least associated with the genetic variations 
in SNCA gene. The mouse model, among many others, has strong advantages for studying 
complex genetic disorders including PD: inbred strains of the same genetic background, 
sophisticated yet accessible methods of genetic manipulation, and a broad spectrum of phe-
notypical manifestations to cover many of PD symptoms. There is still a tremendous need 
for genetic PD mouse models that can recapitulate at least the degeneration of dopaminergic 
neurons in a manageable time window because the ultimate goal in PD research would be 
the prevention or halting of the degenerative processes of these neurons and others [100]. 
However, in comparison with toxin models, the genetic models are at the early stages of be-
havioral and pharmacological characterization, and the phenotypical characterization of the 
non-motor symptoms in genetic mouse models constitutes an emerging area of research [97]. 
The enteric nervous system abnormalities preceding the central nervous system changes 
and α-synuclein-positive aggregates in the enteric ganglia have been reported in mice trans-
genic for artificial chromosomes containing PD-associated α-synuclein (A53T or A30P of 
the human SNCA gene) mutations [101]. Lee et al. have shown that injection of the total 
brain extract from Dementia with Lewy bodies patients into the gastric walls of α-synuclein 
A53T transgenic mice resulted in an accumulation of α-synuclein aggregates in the enteric 
neurons. In contrast, injection of control brain extract failed to produce the aggregates. The 
results suggest that once α-synuclein aggregates are formed in some neurons in the gastroin-
testinal tract, they can spread to a larger neuronal population in the enteric nervous system, 
thereby increasing the chance to propagate the aggregates to the central nervous system [102].
Mice that overexpress wild-type α-synuclein under the Thy1 promoter has also been 
examined for the presence of the non-motor complications [103]. These animals exhibited 
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a progressive development of sensorimotor deficits beginning at two months of age, and 
α-synuclein accumulation in multiple brain regions such as the substantia nigra, however 
except the spinal cord. By three months of age the mice displayed olfactory deficits togeth-
er with progressive alterations in circadian rhythms (lower night-time activity) and signs 
of autonomic dysfunction (increased heart rate variability). Beginning around four to six 
months of age cognitive changes became evident as well. These mice also showed decreas-
es in classical tests of anxiety [67, 104]. Another study revealed gastrointestinal dysfunc-
tion exhibited by abnormal colonic motility in 11-month-old mice [105]. Noreen et al. 
have found that gastrointestinal expression of human α-synuclein in this transgenic line 
was limited to efferent fibers projecting from the dorsal motor nucleus of the vagus nerve 
to the enteric nervous system in an α-synuclein A53T transgenic mice model expressed 
under control of the prion promoter (AS mice). Older transgenic mice had a lower den-
sity of human α-synuclein expression in the gastrointestinal tract, suggesting an age-re-
lated disruption of efferent vagal fibers in this model. At the same time, mice developed 
age-related declines in stool frequency and gastric emptying consistent with those seen in 
human PD [106].
Zhang et al. have also found that α-synuclein A53T transgenic mice at 6 months or 
older displayed a deficit in odor discrimination and odor detection without any motor 
deficit and nigral dopaminergic neuron loss. In 10 months old α-synuclein A53T transge-
nic mice compared to wildtype littermates, dopaminergic neurons were found increased in 
glomerular layer, accompanied with an increase in tyrosine hydroxylase activity as well as 
a marked decrease in cholinergic neurons in mitral cell layer and a decrease in acetylcho-
linesterase activity, which might resemble the observation that olfactory dysfunction usually 
precedes motor deficits in PD patients [107]. At the early stages of the disease in α-synuclein 
over-expressing mice, α-synuclein depositions are more widespread in the olfactory nucle-
us, olfactory tubercle, piriform cortex and lateral entorhinal cortex than in the substantia 
nigra, indicating that pathways involved in these earlier symptoms are the most vulnerable 
to pathophysiological changes [108]. 
However, there is no obvious dopaminergic neuronal loss in most α-synuclein transgenic 
mice, mechanistic studies of dopaminergic neuronal death by α-synuclein have been aided 
through the study of the impact of α-synuclein expression following MPTP intoxication. 
Mitochondrial dysfunction appears to be sufficient to induce α-synuclein aggregation and 
downstream toxicity for dopaminergic neuronal loss in MPTP mouse models. As expected, 
the dopaminergic neurons of α-synuclein transgenic mice show more sensitivity for mit 
chondrial toxins [102]. 
Unfortunately, rodent models of PD are difficult to mimic the non-motor symptoms of 
PD, such as depression, anxiety and emotional abnormalities. Brain anatomy and neuronal 
circuitry are significantly different between primates and rodents. Non-human primates 
would serve as good animal models to uncover the non-motor behavioral changes that may 
mimic early clinical symptoms in PD and would also be valuable for identifying biomark-
ers [109]. Niu et al. have established transgenic PD rhesus monkeys that express mutant 
α-synuclein (A53T). The A53T monkey model allowed to identify cognitive defects and 
anxiety-like behaviors, without detectable sleeping disorders, as early phenotypes [110]. 
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Compared with toxin-induced PD animal models, transgenic PD models should show 
more stable and replicable pathological changes and phenotypes, which are critical for de-
veloping effective treatments [110]. 
Studies of pathological mechanisms that underline the conformational change and ag-
gregation of α-synuclein, as well as those involving the formation of pathogens that can be 
transmitted trans-synaptically to interconnected nerve cells, cannot be performed on for-
malin-fixed autopsy tissue [8]. It is also crucial to differentiate physiologic and pathological 
forms of α-synuclein with appropriate histological stains. Traditional staining shows Lewy 
bodies to be eosinophilic, but α-synuclein immunohistochemistry (antibodies to the amino- 
and carboxyl-terminal sequences) is now the standard method of localizing Lewy bodies 
and Lewy neurites in tissue specimens [111]. Alpha-synuclein is a normal constituent of 
neurons and is expected to be present in a soluble form. This must be distinguished from 
the phosphorylated pathological α-synuclein that forms β-rich sheets and can be detected 
with either appropriate antibodies or stains for Thioflavin-S [112]. 
A wide range of models, even evolutionarily remote, have been used to study Parkin-
son’s disease together with its various complications. Yeast, worms, fruit flies or fish can be 
useful for studying cellular processes involved in the pathogenesis of neurodegeneration 
and Parkinson’s disease, such as apoptosis, autophagy, oxidative stress, protein misfold-
ing and degradation or vesicle-mediated transport, however cannot replicate the loss of 
neurons in the brain. Rodents and non-human primates are another important scientific 
resource but the limitations of these models must be kept in mind when interpreting re-
sults, since none of them completely reproduces the clinical symptoms and pathology seen 
in PD patients so far. Non-human primate models are anatomically, physiologically, and 
behaviorally more similar to humans, but they are rarely used because of cost and ethical 
concerns [49].
Because of these limitations, some studies are still best done in the clinic. A search for 
noninvasive biomarkers of PD sets a good example of this type to study. If one is to identify 
blood biomarkers of PD, the investigation could be done directly and therefore the results 
obtained from the study would be directly applicable to the patients [49]. The identifica-
tion of specific biomarkers and validation of some candidate proteins is needed [113, 114], 
since the diagnosis of Parkinson’s disease is currently assessed by the clinical evaluation of 
extrapyramidal signs [115, 116].
The connectivity between the enteric and the central nervous system via the vagus nerve 
probably play a critical role in the progression of PD so the best but challenging scenario 
would be to design a human-based enteric nervous system model [8], which would pro-
vide more credible insight into the mechanism of α-synuclein aggregation and transmission 
among Parkinson’s disease patients.
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